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o Not Put Off Until Tomorrow
hat You Can Do Today*
avid Antoniucci, MD
lorence, Italy
ore than 30 years ago the hypothesis of an interventional
pproach in patients with unstable angina or non–ST-
egment elevation myocardial infarction (NSTEMI) was
onsidered only after a “cooling-off” period. This negative
ttitude was in part justified by the lack of effective antithrom-
otic adjunctive therapies and devices in the management of
esion containing thrombus and the subsequent early hazard of
ercutaneous coronary intervention (PCI). The delay—many
ays or weeks after hospital admission—to interventional
reatment could result in an apparent stabilization of the
cute coronary syndrome (ACS) with a high incidence of
arly recurrent ischemia or nonfatal myocardial infarction
MI) in the more favorable cases or in a definitive “cooling”
f the patients.
See page 1416
During this long period many trials comparing an early
nvasive strategy with a conservative strategy in patients with
nstable angina or NSTEMI have produced conflicting
esults that have delayed the current general consensus
egarding the benefit of an early invasive strategy, which is
ore evident in high-risk patients and mainly driven by the
ecrease in MI and the need for percutaneous or surgical
oronary revascularization. This troubled history might be
xplained at least in part by the design of most studies that
andomized patients before cardiac catheterization and the
se of a wide temporal windows—from 24 to 48 h to 5
ays—for the definition of “early” intervention. Random-
zation before cardiac catheterization resulted in the enrol-
ent of a high percentage (30%) of patients who did not
eceive coronary revascularization, because of mild or absent
therosclerotic coronary artery disease in most of them,
aking the comparison of an early invasive strategy versus a
onservative or a delayed invasive strategy in selected pa-
ients distorted by the high number of patients at low risk of
vents whatever the strategy adopted. The use of temporal
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or thea
merican College of Cardiology.
From the Division of Cardiology, Careggi Hospital, Florence, Italy.indows as long as 24 to 48 h to several days for the
efinition of an early treatment hides the potential benefit of
true “early” treatment (within 24 h of patient presentation)
nd contributes to maintaining considerable uncertainty about
he optimal timing of cardiac catheterization and revascu-
arization for patients with unstable angina or NSTEMI.
The study by Sorajja et al. (1) in this issue of the Journal
vercame these 2 critical points and provides important data on
he impact of delay to PCI on clinical outcome in the large
ohort of patients with ACS enrolled in the ACUITY (Acute
atheterization and Urgent Intervention Triage strategY) trial
ho underwent PCI (2). Patients who underwent PCI (7,749
atients) were stratified by time from hospital presentation to
CI into 3 groups:8 h, 8 to 24 h, and24 h. A delay to PCI
24 h after clinical presentation was associated with 50%
ncrease in 30-day and 1-year mortality as compared with
atients who were treated earlier. Moreover, true “early” PCI
as associated with a decreased rate of nonfatal MI. The
ncremental risk of death attributable to PCI delay24 h was
reatest in high-risk patients.
The study results are consistent with those of the ISAR-
OOL (Intracoronary Stenting With Antithrombotic Reg-
men Cooling-Off) trial (3). This elegant study is the only
andomized trial comparing early intervention (delay to PCI
6 h) with prolonged (3 to 5 days) maximized antithrom-
otic therapy before intervention in patients with ACS. The
tudy involved 410 patients, and the primary end point was
he composite of death or large MI at 30 days. The primary
nd point rate was 11.6% in patients allocated to delayed
ntervention and 5.9% in patients receiving early interven-
ion (p  0.04). Very importantly, the difference between
roups was driven by the events that occurred before cardiac
atheterization, whereas the rates of post-procedural events
ere identical in the 2 groups. This study has been criti-
ized, mainly because of the small number of patients, and
he results were in the opposite direction of the study
ypothesis that was used for the calculation of the sample
ize (prolonged antithrombotic treatment before interven-
ion would result in a relative risk reduction of death and MI
f 60% as compared with early intervention). Nevertheless,
he study has several strengths, such as the strict criteria used
or the definition of ACS and the temporal windows for
ntervention and the optimal antithrombotic treatment in both
rms that included heparin, glycoprotein IIb/IIIa inhibitors, a
00-mg loading dose of clopidogrel, and aspirin.
The study of Sorajja et al. (1), based on a very large
ohort of patients who received PCI, strongly supports the
esults of the ISAR-COOL (Intracoronary Stenting With
ntithrombotic Regimen Cooling Off) trial and avoids the
onfounding effect of the substantial percentage of low- or
ery-low-risk patients who received medical therapy after
ardiac catheterization (32% in the entire cohort of the
CUITY trial) (2). As expected, major differences in MI
nd death rates were revealed in high-risk patients. Even
mong the low-risk patients there was a significantly higher
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PCI Delay in ACS April 6, 2010:1425–6-year mortality rate among those who had PCI24 h after
linical presentation than among patients who had earlier
CI: no deaths at 1 year in the Thrombolysis In Myocardial
nfarction (TIMI) risk score 1 to 2 subgroup with a
ime-to-PCI 8 h, and 2% in the subgroup with a
ime-to-PCI 24 h. This point is really important, because
t outlines a major limitation of risk-scoring before cardiac
atheterization in the individual patient and at the same
ime weakens a strategy of deferring for expedited cardiac
atheterization only patients with a high risk score. A low
IMI risk score might correspond to a very-high-risk
ngiographic profile. This event is frequent and confirmed
lso by early coronary angiography in the PCI-ACUITY
atient cohort (1). Nearly one-half of patients who under-
ent coronary angiography within 24 h of presentation had
baseline target vessel TIMI flow grade 2. A strategy of
laque passivation before PCI could be effective in decreas-
ng PCI complications in the portion of patients who
pontaneously or with an intensive antithrombotic treat-
ent may experience improved coronary flow. Also in this
ubset of patients with an initial favorable course, the
ncidence of recurrent refractory ischemia is high—as is MI
ven after successful emergency PCI—whereas a remarkable
ortion of patients will not respond to antithrombotic
herapy: in the ACUITY PCI study, 38% of patients who
nderwent coronary angiography with a delay 24 h still
ad a baseline target vessel TIMI flow grade 3 (1).
nother important finding provided by this study is that the
enefit in terms of mortality and MI provided by early PCI
t 1 month is maintained at 1-year follow-up, whereas most
f the previous studies provide short follow-up data.
At first sight the results of this study conflict with those of
contemporary umpteenth randomized trial comparing an
arly invasive strategy with a delayed invasive strategy in ACS
atients, the TIMACS (Timing of Intervention in Acute
oronary Syndromes) trial (4). This study, which enrolled
,031 patients with ACS, compared an early invasive strategy
coronary angiography performed within 24 h) with a delayed
nvasive strategy (coronary angiography performed36 h after
andomization). The difference between groups in the primary
tudy end point (6-month death, MI, stroke) rate was not
ignificant (9.6% of patients in the early-intervention group,
nd 11.3% in the delayed intervention group) (hazard ratio KHR]: 0.85; 95% confidence interval [CI]: 0.68 to 1.06, p 
.15). As in previous trials with similar results, the lack of
ignificant difference in outcome between the 2 strategies
ight be explained by the fact that the study could be
nderpowered for the primary end point (the study was
topped prematurely because of recruitment challenges), in-
olved mainly low-intermediate-risk patients with a subse-
uent low rate of PCI (60% of patients underwent PCI),
ith a median time to PCI of 16 h in the early invasive strategy
roup. These possible explanations are made plausible because
arly intervention improved the primary outcome in the one-
hird of patients who were at high risk (HR: 0.65; 95% CI:
.48 to 0.89) and the secondary outcome (composite of death,
I, and refractory ischemia) in the entire cohort of patients
HR: 0.72; 95% CI: 0.58 to 0.89, p  0.003) (4).
This study by the ACUITY investigators adds to the
ody of knowledge about how best to care for patients
resenting with ACS. Refined adjunctive antithrombotic
herapies and, eventually, thrombectomy devices overcome
he potential hazard of early PCI in ACS patients. Acute
oronary syndrome patients, particularly those with positive
roponins and/or dynamic electrocardiographic changes,
hould be immediately triaged to catheterization laboratory-
ased diagnosis and treatment.
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ivision of Cardiology, Careggi Hospital, Viale Morgagni, Flo-
ence I-50135, Italy. E-mail: david.antoniucci@virgilio.it.
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